Advicenne S.A.

Paris Stock Exchange ALDVI.PA

Advicenne S.A. Operating Cash Flow for the year ending December 31, 2023: USD -6.61 M

Advicenne S.A. Operating Cash Flow is USD -6.61 M for the year ending December 31, 2023, a 32.46% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Advicenne S.A. Operating Cash Flow for the year ending December 31, 2022 was USD -9.79 M, a 31.36% change year over year.
  • Advicenne S.A. Operating Cash Flow for the year ending December 31, 2021 was USD -14.26 M, a 0.19% change year over year.
  • Advicenne S.A. Operating Cash Flow for the year ending December 31, 2020 was USD -14.29 M, a -34.34% change year over year.
  • Advicenne S.A. Operating Cash Flow for the year ending December 31, 2019 was USD -10.63 M, a 8.74% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
SV Wall Street
Paris Stock Exchange: ALDVI.PA

Advicenne S.A.

CEO Mr. Didier Laurens
IPO Date Dec. 6, 2017
Location France
Headquarters 3ème étage 262
Employees 21
Sector Healthcare
Industries
Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Fertilizers Glass
Description

Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.

StockViz Staff

February 6, 2025

Any question? Send us an email